EFILA (commonly referred to as EFILA Multi-Target Cellular Nutrition Intervention) is a cutting-edge health intervention solution that integrates synthetic biology and cellular medicine. It primarily targets chronic metabolic diseases, particularly Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD, now widely known as MASLD).
Its core concepts and technical features can be summarized in the following key dimensions:
Core Mechanisms: Multi-Target & Cellular Nutrition
Unlike traditional medicine, which often focuses on a single target (such as a single receptor or enzyme), EFILA emphasizes "multi-target synergy."
Cellular-Level Repair: Rather than relying solely on exogenous blood sugar reduction, it directly acts on damaged pancreatic \beta-cells and hepatic cells through highly bioavailable cellular nutrients.
Reversing Mitochondrial Dysfunction: It optimizes mitochondria—the cell's energy powerhouse—to reduce oxidative stress and chronic inflammation.
Improving Insulin Resistance: By repairing cell membrane receptors and intracellular signaling pathways, it restores the body's sensitivity to insulin.
Technical Foundation: Driven by Synthetic Biology
The underlying R&D of EFILA relies heavily on synthetic biology technologies:
High Purity & High Bioactivity: Utilizing engineered microorganisms or biocatalytic techniques, it bio-synthesizes specific nutritional components (such as specific small-molecule peptides, high-purity plant extract derivatives, or cytokine precursors) with maximum purity and bioactivity.
Overcoming Absorption Barriers: Through precise molecular structure design, it enhances the stability and intestinal absorption rate of these ingredients, ensuring targeted delivery to key organs (e.g., the liver and pancreas).
R&D Background & International Regulatory Approvals
The solution is backed by a strong international research background and cross-border regulatory compliance:
Joint R&D Background: Supported by core academic and technology transfer expertise from A*STAR (Agency for Science, Technology and Research), Singapore's premier research institution.
Dual-Country Regulatory Approval: It has secured regulatory approvals from health and food authorities in both Singapore and South Korea, granting it legal compliance for international commercialization and clinical nutritional intervention.
Commercial & Clinical Positioning
In the fields of healthcare and clinical nutrition, EFILA is positioned as a "non-pharmaceutical, side-effect-free metabolic reversal solution." It is frequently utilized as a core intervention within Chronic Disease Management Systems (CDMS). When paired with precise dietary management and data monitoring, it helps early- to mid-stage diabetes and fatty liver patients reduce drug dependence and restore the body's natural self-healing capacity.
EFILA™ is an abbreviation for "Enhanced Functional Insulin and Lifestyle Algorithm." It is not a single nutrient, but a comprehensive clinical intervention program designed by functional medicine experts to reverse type 2 diabetes. Its core is the systematic application of "multi-target cellular nutritional intervention."
At EFILA™, we believe true wellness begins at the cellular level. Our 100% natural formula, crafted from bioengineered mushroom mycelium, delivers targeted cellular nutrition to:
✓ Protect pancreatic beta cells from apoptosis
✓ Promote healthy insulin function through natural metabolic support
✓ Support your body’s innate ability to manage glucose
Why EFILA™?
🌿 IP Fortress: The World’s First Two Patented Strains 6 patents (KR/CN/PCT)
📊 70+ Clinical Cases, Improvement in Insulin Resistance | Kyung Hee University validated
Cellular Nutrition: The Foundation of Metabolic Health
From Cell to System: EFILA’s Triple-Action Precision Powers Beta Cell Health and Insulin Balance
Our Journey: From Forest Discovery to Global Innovation
Rooted in Nature, Validated by Science
2005: A Breakthrough in the Korean Forests
-
Foundational Discovery: Dr. Kim Byoungcheon, a visionary scientist with a PhD in Biomedical Sciences (Western California Medical University), discovers Ceriporia lacerata — a rare medicinal mushroom growing on Korean pine trees.
-
Initial Findings: In Vitro and In Vivo studies revealed its extraordinary potential to lower blood glucose level and protect pancreatic beta cells from apoptosis, etc., sparking a 20-year R&D mission
2005–2015: Decoding Nature’s Blueprint
-
Strain Optimization: Patented fermentation technology refines Ceriporia lacerata into a standardized bioactive extract.
-
Preclinical Validation:
✓ 4 Toxicity Tests — Confirmed safety across organ systems.
✓ Animal Studies — Demonstrated 30% blood sugar reduction in diabetic models (Int. J. Mol. Med, 2013).
-
Global Recognition: Dr. Kim awarded the Grand Prize at EURO INVENT 2015 for advancing natural diabetes solutions.
2016–2021: From Lab to Life
-
Human Trials Begin: Phase I trials at Kyung Hee University validate:
✓ 7.7 mg/dL fasting glucose reduction (BMC Complementary Medicine, 2023).
✓ Zero adverse effects across 70+ participants.
-
Patented Evolution:
✓ Ceriporia lacerata K1 — 3 patents in KR.
✓ Irpex lacteus I.K —1 patent in KR; 1 patent in CN, 1 patent in PCT.
2022–Present: Rewriting Diabetes Care
-
EFILA™ : Obtain global patents for EFILA — a compound derived from dual-strain fermentation, targeting:
✓ Beta cell regeneration (Journal of Diabetes Research, 2022).
✓ Systemic insulin sensitivity (Food Sci Biotechnol, 2021).
-
Industry Chain Mastery: Full-cycle control from strain cultivation (KACC-certified) to industrial standardization of production.
-
Global Vision: Partnering with health supplement/pharmaceutical companies to bring this unique dietary supplement to help 500M+ at-risk patients.
Committed to Quality. Dedicated to Consumer Confidence.
Health Sciences Authority (HSA) Voluntary Notification Scheme
At EFILA, consumer safety and product quality are our highest priorities. To reinforce this commitment, selected EFILA health supplements have been submitted under the Singapore Health Sciences Authority's (HSA) Voluntary Notification Scheme (VNS).
The VNS serves as a trusted reference for consumers by providing a database of health supplements and traditional medicines that have fulfilled the applicable notification requirements, including safety, quality and labelling standards. This initiative also enhances product traceability, giving consumers greater assurance when choosing health supplements.
The EFILA Promise
EFILA is dedicated to developing premium nutritional supplements that combine quality ingredients with stringent manufacturing practices. Every product is carefully formulated and produced in facilities that comply with internationally recognised Good Manufacturing Practice (GMP) standards, ensuring consistent quality throughout every stage of production.
From ingredient sourcing and manufacturing to quality control, each step is guided by rigorous processes designed to deliver products that consumers can trust. Our commitment extends beyond meeting regulatory requirements—we continually strive to uphold the highest standards of product excellence, safety and reliability.
By participating in the HSA Voluntary Notification Scheme, EFILA demonstrates its ongoing commitment to transparency, regulatory compliance and consumer confidence. We will continue to notify additional eligible products under the scheme as part of our dedication to providing safe, high-quality health supplements.
EFILA Products Notified Under the HSA Voluntary Notification Scheme
• Active Ingredient:
CL-K1®:
- Ceriporia Lacerata Culture Medium
- Submerged Culture of Ceriporia lacerata mycelium
• Notified Product:
| EFILA BLOOD SUGAR SUPPORT JELLY |
EFILA ADVANCE BLOOD SUGAR SUPPORT |
 |
 |
| VNS No.: VNS-2026-01-00049 |
VNS No.: VNS-2025-07-00175 |
Longrunn Medical x A*STAR: Pioneering Natural Solutions for Diabetes Care
Longrunn Medical Technologies is proud to announce a strategic collaboration with Singapore’s Agency for Science, Technology and Research (A*STAR) under the T-UP Programme.
Research Focus
This one-year project investigates the antidiabetic potential of Ceriporia lacerata K1 (CLK1), a rare white-rot fungus with unique bioactive compounds. The research will focus on:
• Large-scale cultivation of CLK1 and extraction of active metabolites
• Safety and efficacy validation through cytotoxicity and antidiabetic assays
• Elucidating molecular mechanisms (e.g., PI3K/Akt, AMPK pathways)
• Identifying and characterizing active antidiabetic compounds within CLK1, and advancing them into consumer-ready formats such as dietary supplements, functional foods, and complementary medicines
Strategic Significance
Through this partnership, Longrunn contributes expertise in nutraceutical innovation, while A*STAR brings world-class scientific research capabilities. Together, we aim to provide safer, natural, and effective solutions for diabetes management.
This collaboration not only addresses one of Singapore’s most pressing health challenges but also strengthens the nation’s position as a hub for translational health research and nutraceutical innovation.
EFILA FDA Development Process & Current Progress
The EFILA® active ingredient has completed comprehensive pre-clinical validation, including toxicology, efficacy, and pharmacological studies required for IND application.
Completed Research Achievements
1. Strain Development & Characterization
- Isolation, identification, and genetic stability verification of CL-K1
- Established large-scale fermentation process and quality control system
2. Completed GLP Toxicology Studies
- Single-dose acute toxicity
- 4-week DRF (Dose Range Finding) study
- 13-week repeated oral toxicity (Rat & Beagle dog)
→ Demonstrated an excellent safety profile with no toxicity-related mortality or organ damage
3. Genetic Toxicity Studies
- Ames mutagenicity test
- Mouse micronucleus assay
- CHL chromosomal aberration test
→ All negative, confirming no genotoxic or mutagenic risk
4. Safety Pharmacology
- CNS safety study
- Cardiovascular safety, including hERG channel
→ No adverse pharmacological effects observed
5. Pharmacodynamic / Efficacy Studies
- OGTT glucose tolerance improvement (ICR mouse)
- Long-term metabolic improvement in db/db mice
- β-cell protection mechanism (anti-apoptosis, anti-oxidative stress)
- GLUT4 transporter activation mechanism
→ Confirmed multi-target antidiabetic potential of CL-K1
6. Completed Phase 1 Human Clinical Trial
- Conducted at Kyung Hee University, Korea
Demonstrated good tolerability and positive metabolic improvement trends
Upcoming Development Milestones
1. Initiate FDA Pre-IND Consultation
Discuss regulatory pathway and clinical protocol with FDA.
2. Proceed with IND Submission
Upon approval, U.S. clinical trials may formally begin.
3. Plan and Conduct Phase 2 & Phase 3 Clinical Trials
- Validate efficacy
- Expand to larger population
- Build long-term safety & dose–response data
4. NDA (New Drug Application) Submission
Prepare full dossier including CMC, toxicology, and clinical data.
5. Expansion to Additional Indications
Based on mechanism-of-action insights:
- Liver metabolic diseases (e.g., NASH)
- Inflammation-associated metabolic disorders
- Obesity & metabolic syndrome
6. Post-Marketing Long-Term Safety Evaluation
Generate real-world evidence (RWE) after commercial launch.
Why Trust EFILA?
- 20 years’ basic and clinical research, 9 SCI papers: Rigorously validated by institutions like Kyung Hee University,
-
Ethics in Action:
✓ 100% natural, traceable ingredients.
